Maevskaya M.V., Kotovskaya Yu.V., Ivashkin V.T., Tkacheva O.N., Troshina E.A.,
Shestakova M.V., Breder V.V., Geyvandova N.I., Doshchitsin V.L., Dudinskaya E.N.,
Ershova E.V., Kodzoeva Kh.B., Komshilova K.A., Korochanskaya N.V., Mayorov A.Yu.,
Mishina E.E., Nadinskaia M.Yu., Nikitin I.G., Pogosova N.V., Tarzimanova A.I.,
Shamkhalova M.Sh. Nacionalnyj konsensus dlya vrachej po vedeniyu vzroslyh
pacientov s nealkogolnoj zhirovoj bolezn’yu pecheni i ee osnovnymi komorbidnymi sostoyaniyami [The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities]. Ter Arkhiv, 2022, vol. 94, no. 2, рр. 216–253. doi: 10.26442/
00403660.2022.02.201363. (in Russian).
2. Younossi Z.M., Koenig A.B., Abdelatif D., et al. Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence,
and Outcomes. Hepatology. 2016, vol 64, no. 1, pp. 73-84. doi: 10.1002/
hep.28431.
3. Drapkina O.M., Ivashkin V.T. Epidemiologicheskie osobennosti nealkogolnoj zhirovoj
bolezni pecheni v rossii (rezultaty otkrytogo mnogocentrovogo prospektivnogo
issledovaniya-nablyudeniya DIREG L 01903) [Epidemiologic features of non- alcoholic fatty liver disease in Russia (Results of open multicenter prospective observational study DIREG L 01903)]. Russ J Gastroenterol Hepatol Coloproctiol, 2014, vol. 24,
no. 4, pp. 32–38. (in Russian).
4. Evstifeeva S.E., Shalnova S.A., Kutsenko V.A., Yarovaya E.V., Balanova Yu.A., Imaeva
A.E., Kapustina A.V., Muromtseva G.A., Maksimov S.A., Karamnova N.S., Soplenkova A.G., Filichkina E.M., Viktorova I.A., Prishchepa N.N., Redko A.N., Yakushin S.S.,
Drapkina O.M. Rasprostranennost nealkogolnoj zhirovoj bolezni pecheni sredi
naseleniya trudosposobnogo vozrasta: associacii s socialno-demograficheskimi
pokazatelyami i povedencheskimi faktorami riska (DANNYE ESSE-RF-2) [Prevalence
of non-alcoholic fatty liver disease among the working-age population: associations
with socio-demographic indicators and behavioral risk factors (ESSE RF-2 data)].
Kardiovaskulyarnaya terapiya i profilaktika. 2022, vol. 21, no 9, pp. 40–49. doi:
10.15829/1728-8800-2022-3356 (in Russian).
5. Younossi Z.M., Stepanova M., Afendy M., et al. Changes in the prevalence of the
most common causes of chronic liver diseases in the United States from 1988
to 2008. Clin Gastroenterol Hepatol, 2011, vol. 9, no. 6, pp. 524–530. doi: 10.1016/
j.cgh.2011.03.020.
6. Day C.P., James O.F.Steatohepatitis: a tale of two “hits”? Gastroenterology, 1998, vol. 114,
pp. 842–845. doi: 10.1016/s0016-5085(98)70599-2.
7. Xian Y.X., Weng J.P., Xu F. MAFLD vs. NAFLD: shared features and potential changes
in epidemiology, pathophysiology, diagnosis, and pharmacotherapy. Chin Med J.
2020, vol. 134, pp. 8 doi: 10.1097/ CM9.0000000000001263.
8. Wu Y., Zheng Q., Zou B., Yeo Y.H., Li X., Li J., et al. The epidemiology of NAFLD
in Mainland China with analysis by adjusted gross regional domestic product:
a meta-analysis. Hepatol Int, 2020, vol. 12, pp. 259–269. doi: 10.1007/s12072-
020-10023-3.
9. Maev I.V., Andreev D.N., Kucheryavyy Yu.A. Prevalence of non-alcoholic fat disease
liver in Russian Federation: meta-analysis. Consilium Medicum, 2023, vol. 25, no. 5,
pp. 313–319. doi: 10.26442/20751753.2023.5.202155.
10. Le M.H., Yeo Y.H., Li X., et al. 2019 Global NAFLD Prevalence: A Systematic Review
and Meta-analysis. Clin Gastroenterol Hepatol, 2022, vol. 20, no. 12, pp. 2809-2817.
doi: 10.1097/HC9.0000000000000244.
11. Younossi Z.M., Golabi P., Paik J.M., et al. The global epidemiology of nonalcoholic
fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology, 2023, vol. 77, no. 4, pp. 1335-1347. doi: 10.1097/
HEP.0000000000000004.
12.Kotovskaya Yu.V. Non-alcoholic fatty liver disease and cardiovascular risks:
A review. Consilium Medicum, 2023, vol. 25, no. 4, pp. 253–258. doi: 10.26442/
20751753.2023.4.202275.
13. Rinella M.E., Lazarus J.V., Ratziu V., Francque S.M., Sanyal A.J., Kanwal, F., Romero D.,
et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023. doi: 10.1097/HEP.0000000000000520.
14. Eslam M., Sanyal A.J., George J., Sanyal A., Neuschwander-Tetri B., Tiribelli C., et al.
MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty
Liver Disease. Gastroenterology. 2020, vol. 158, pp. 1999–2014. doi: 10.1053/
j.gastro.2019.11.312.
15. Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al.
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020, vol. 7, pp. 202–209. doi:
10.1016/j.jhep.2020.03.039.
16. Pakhomova I.G., Knorring G.Yu. Nealkogolnaya zhirovaya bolezn’ pecheni i serdechno-sosudistaya patologiya: osobennosti vedeniya pacienta na klinicheskom
primere [Non-alcoholic fatty liver disease and cardiovascular pathology: features
of patient management on a clinical example]. Experimental Clin Gastroenterology, 2022, no. 9(205), pp. 290–297. doi: 10.31146/1682-8658-ecg-205-9-290-
297. (in Russian).
17. Ivashkin V.T., Maevskaya M.V., Zharkova M.S., Kotovskaya Yu.V., Tkacheva O.N.,
Troshina E.A., Shestakova M.V., Maev I.V., Breder V.V., Gheivandova N.I., Doshchitsin V.L.,
Dudinskaya E.N., Ershova E.V., Kodzoeva Kh.B., Komshilova K.A., Korochanskaya N.V.,
Mayorov A.Yu., Mishina E.E., Nadinskaya M.Yu., Nikitin I.G., Pogosova N.V., Tarzimanova A.I., Shamkha-lova M.Sh. Klinicheskie rekomendacii Rossijskogo obshchestva po izucheniyu pecheni, Rossijskoj gastroenterologicheskoj associacii,
Rossijskoj associacii endokrinologov, Rossijskoj associacii gerontologov i geriatrov
i Nacionalnogo obshchestva profilakticheskoj kardiologii po diagnostike i lecheniyu
nealkogolnoj zhirovoj bolezni pecheni [Clinical Practice Guidelines of the Russian
Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians
and National Society for Preventive Cardiology on Diagnosis and Treatment
of Non-Alcoholic Liver Disease]. Russ J Gastroenterol Hepatol Coloproctiol, 2022,
vol. 32, no 4, pp. 104–140. doi: 10.22416/1382-4376-2022-32-4-104-140.
(in Russian).
18. Pavlov Ch.S., Kuznetsova Е.A., Arslanyan M.G., Semenistaya M.Ch., Glushenkov D.V., Nikolenko V.N. Nealkogolnaya zhirovaya bolezn pecheni: sovremennye koncepcii etiologii, patogeneza, diagnostiki i lecheniya [Non-alcoholic
fatty liver disease: modern concepts of etiology, pathogenesis]. Med
Vestn Severnogo Kavkaza, 2017, vol. 12, no. 2, pp. 230-234. doi: 10.14300/
mnnc.2017.1206.
19. Drapkina O.M., Yafarova A.A. Nealkogolnaya zhirovaya bolezn pecheni i serdechno-sosudistyj risk: sostoyanie problemy [Non-Alcoholic Fatty Liver Disease
and Cardiovascular Risk: Scientific Problem State]. Rat Pharmacother Cardiology,
2017, vol. 13, no. 5, pp. 645-650. doi: 10.20996/1819-6446-2017-13-5-645-650.
(in Russian).
20.Lambert J.E., Ramos-Roman M.A., Browning J.D., Parks E.J. Increased de novo
lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology, 2014, vol. 146, pp. 726–35. doi: 10.1053/
j.gastro.2013.11.049.
21. Younossi Z. Global epidemiology of nonalcoholic fatty liver desease – Meta-analytic assessment of prevalence, incidence and outcomes. Hepatology. 2016, vol. 64,
pp. 73–84. doi: 10.1002/hep.28431.
22.Zhou Y.Y., Zhou X.D., Wu S.J., Fan D.H., Van Poucke S., Chen Y.P., Fu S.W., Zheng M.H. Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: A systematic review and meta-analysis. Hepatol Commun, 2018, vol. 2, pp. 376–392. doi:
10.1002/hep4.115.
23. Mantovani A., Dauriz M., Sandri D., Bonapace S., Zoppini G., Tilg H., Byrne C.D.,
Targher G. Association between non-alcoholic fatty liver disease and risk of atrial
fibrillation in adult individuals: An updated meta-analysis. Liver Int, 2019, vol. 39,
pp. 758–769. doi: 10.1111/liv.14044.
24.Cai X., Zheng S., Liu Y., Zhang Y., Lu J., Huang Y. Nonalcoholic fatty liver disease
is associated with increased risk of atrial fibrillation. Liver Int, 2020, vol. 40,
pp. 1594–1600. doi: 10.1111/liv.14461.
25. Wijarnpreecha K., Lou S., Panjawatanan P., Cheungpasitporn W., Pungpapong S.,
Lukens F.J., Ungprasert P. Association between diastolic cardiac dysfunction and
nonalcoholic fatty liver disease: a systematic review and meta-analysis. Dig Liver
Dis, 2018, vol. 50, pp. 1166–1175. doi: 10.1016/j.dld.2018.09.004.
26.Cheungpasitporn W., Ungprasert P. Association between cardiac conduction defect
and nonalcoholic fatty liver disease: a systematic review and meta-analysis.
Ann Gastroenterol, 2020, vol. 33, pp. 661–666. doi: 10.20524/aog.2020.0535.
27. Di Minno M.N., Di Minno A., Ambrosino P., Songia P., Tremoli E., Poggio P. Aortic
valve sclerosis as a marker of atherosclerosis: novel insights from hepatic steatosis.
Int J Cardiol, 2016, vol. 217, pp. 1–6. doi: 10.1016/j.ijcard.2016.04.162.
28. Muzurović E., Peng C.C., Belanger M.J., Sanoudou D., Mikhailidis D.P., Mantzoros C.S.
Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: a Review of Shared
Cardiometabolic Risk Factors. Hypertension. 2022, vol. 79, no 7, pp. 1319-1326. doi:
10.1161/HYPERTENSIONAHA.122.17982.
29. Oikonomou D., Georgiopoulos G., Katsi V., Kourek C., Tsioufis C., Alexopoulou A., Koutli E.,
Tousoulis D. Non-alcoholic fatty liver disease and hypertension: coprevalent or correlated? Eur
J Gastroenterol Hepatol. 2018, vol. 30, pp. 979–985. doi: 10.1097/MEG.0000000000001191.
30. Donati G., Stagni B., Piscaglia F., Venturoli N., Morselli-Labate A.M., Rasciti L.,
Bolondi L. Increased prevalence of fatty liver in arterial hypertensive patients
with normal liver enzymes: role of insulin resistance. Gut, 2004, vol. 53, no 7,
pp. 1020-3. doi: 10.1136/gut.2003.027086.
31. Zhao Y.C., Zhao G.J., Chen Z., She Z.G., Cai J., Li H. Nonalcoholic Fatty Liver Disease:
An Emerging Driver of Hypertension. Hypertension, 2020, vol. 75, no 2, pp. 275-284.
doi: 10.1161/HYPERTENSIONAHA.119.13419.
32. Ma J., Hwang S.J., Pedley A., Massaro J.M., Hoffmann U., Chung R.T., Benjamin E.J.,
Levy D., Fox C.S., Long M.T. Bi-directional analysis between fatty liver and cardiovascular disease risk factors. J Hepatol, 2017, vol. 66, pp. 390–397. doi: 10.1016/
j.jhep.2016.09.022.
33. Targher G., Bertolini L., Rodella S., Tessari R., Zenari L., Lippi G., Arcaro G. Nonalcoholic fatty liver disease is independently associated with an increased incidence
of cardiovascular events in type 2 diabetic patients. Diabetes Care, 2007, vol. 30, no. 8,
pp. 2119–2121. doi: 10.2337/dc07-0349.
34.Mahfood H.T., Hamdeh S., Kanmanthareddy A., Alla V.M. Nonalcoholic fatty liver
disease and the risk of clinical cardiovascular events: A systematic review
and meta-analysis. Diabetes Metab Syndr, 2017, vol. 11, no. 1, pp. 209-S216. doi:
10.1016/j.dsx.2016.12.033.
35. Targher G., Byrne C.D., Lonardo A., Zoppini G., Barbui C. Non-alcoholic fatty liver
disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol, 2016,
vol. 65, no. 3, pp. 589–600. doi: 10.1016/j.jhep.2016.05.013.